Huntsville, AL – According to filings with the U.S. Securities and Exchange Commission, Serina Therapeutics is raising $3,650,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Randall Moreadith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Serina Therapeutics
Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short. Our proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is broad, customizable and versatile, and can be dosed via IV, SC or IM routes.

To learn more about Serina Therapeutics, visit http://serinatherapeutics.com/

Contact:
Randall Moreadith, President and Chief Executive Officer
256-327-0566
https://www.linkedin.com/in/randall-moreadith-md-phd-143b3313/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved